Bank of New York Mellon’s Acumen Pharmaceuticals ABOS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$332K Buy
+124,377
New +$307K ﹤0.01% 3951
2025
Q2
Sell
-90,258
Closed -$99.3K 4137
2025
Q1
$99.3K Sell
90,258
-2,725
-3% -$3.89K ﹤0.01% 4004
2024
Q4
$160K Hold
92,983
﹤0.01% 3989
2024
Q3
$231K Sell
92,983
-33,439
-26% -$90.7K ﹤0.01% 3870
2024
Q2
$306K Buy
+126,422
New +$402K ﹤0.01% 3809
2022
Q2
Sell
-68,971
Closed -$270K 4579
2022
Q1
$270K Buy
68,971
+49,791
+260% +$271K ﹤0.01% 4075
2021
Q4
$129K Buy
19,180
+1,235
+7% +$13.6K ﹤0.01% 4364
2021
Q3
$266K Buy
+17,945
New +$299K ﹤0.01% 4089

Other funds holding ABOS

Bank of New York Mellon's ABOS Position: Q2 2026 in Review

Bank of New York Mellon opened a new position in Acumen Pharmaceuticals (ABOS) in Q2 2026: 124,377 shares worth $332K. The stake represents ﹤0.01% of the portfolio and ranks #3951 among its holdings. This is a return to the name: Bank of New York Mellon previously reported a position in ABOS as recently as Q1 2025.

Bank of New York Mellon first reported a position in ABOS in Q3 2021 and has held it in 8 quarters since. 26 funds tracked by Wall St. Rank hold ABOS as of Q2 2026.

  • Bank of New York Mellon held 124,377 shares of Acumen Pharmaceuticals worth $332K as of Q2 2026.
  • Acumen Pharmaceuticals was a new Bank of New York Mellon position in Q2 2026.
  • Acumen Pharmaceuticals made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #3951 holding.
  • Bank of New York Mellon first reported a position in Acumen Pharmaceuticals in Q3 2021 and has held it in 8 quarters since.
  • 26 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.